Hypertrophic cardiomyopathy (HCM) is a heterogeneous disease process that leads to variable clinical presentations and outcomes. Many individuals with HCM will remain asymptomatic or only mildly symptomatic throughout life and require no medical intervention. Identification and treatment of symptomatic and high-risk patients and their families remains the cornerstone of management. Indicated treatment is aimed at three interrelated processes of heart failure, sudden cardiac death, and atrial fibrillation.
KeywordsGenetic Cardiomyopathy Hypertrophy Sudden cardiac death Syncope Heart failure Dynamic outflow tract obstruction Septal anterior motion
- 11.Gersh BJ, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;58(25):2703–38.CrossRefPubMedGoogle Scholar